GRFS: Grifols SA Sotuvga nisbatan narx
Hisoblangan narx-sotuvlar nisbati Grifols, S.A. (GRFS) kompaniyasining kam uchraydigan patologiyalar bozorida yuqori ulushga ega bo'lgan B2B plazma asosidagi dori vositalari segmentidagi global yetakchilik mavqeini ko'rsatadi. 0.30 qiymati xarajatlarni kamaytirish va xomashyo yig'ishning o'sishi fonida so'nggi metrika qiymatini aks ettiradi. Kirishning yuqori to'siqlari va resurslarning tanqisligi emitentga hayotni saqlab qoluvchi dori vositalarining narxini belgilash imkoniyatini samarali boshqarishga imkon beradi.
Grifols Group (GRFS) kompaniyasining tahliliy kesimlari
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi haqida ma'lumot:
- aksiyadorlik kapitalining balans qiymati ma'lumotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning kapitalga nisbati koeffitsiyenti Grifols, S.A.|GRFS - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning o'z kapitaliga nisbati Grifols Biemat|GRFS - Kompaniya qarzlari|Balans qiymatiga qarzlar Grifols Group|GRFS - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzi Grifols|Oraliq qoplama koeffitsiyenti grifols.com
- foyda va bozor multiplikatorlari tafsilotlari:
GRFS - Sof daromad|Kutilayotgan sof daromad Grifols, S.A.|GRFS - Narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Grifols SA|GRFS - Narx-foyda va o‘sish multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Grifols Group|GRFS - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Grifols|GRFS - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi grifols.com|GRFS - Joriy yilda foyda o'sishi|Keyingi yil uchun bitta aksiya uchun sof foyda o'sishi prognozi Grifols, S.A.
- umumiy tushum va sotuv hajmi ma'lumotlari:
Kompaniyaning fundamental tahlili:GRFS - grifols.com
Grifols, S.A. (GRFS) yuqori texnologiyali plazma derivatlari va diagnostika uskunalarini sotish orqali daromad keltiradi, bu esa P/S koeffitsiyentini biznesning bozor kapitalizatsiyasini uning operatsion hajmlariga nisbatan baholash uchun asosiy ko'rsatkichga aylantiradi. 0.30 ning joriy qiymati investorlarning sotuvlar birligi uchun to'lashga bo'lgan tayyorligini aks ettiradi, joriy P/S dinamikasi esa aktivning haddan tashqari sotib olinganligi yoki qadrsizlanganligini aniqlash uchun ushbu koeffitsiyentni tarixiy ekstremumlar bilan solishtirish imkonini beradi.
Grifols, S.A. raqobatchilari
argenx.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori BNTX (BioNTech)|Abivax Pharma (ABVX) - Sotuvga nisbatan narx|ADMA Bio - P/S multiplikatori|Narx/daromad multiplikatori Protagonist Corp (PTGX)|Immunovant, Inc. (IMVT) - Narxning daromadga nisbati|kiniksa.com - Bozor kapitallashuvining daromadga nisbati|ADPT (Adaptive Biotechnologies Corporation) - P/S multiplikatori|Celldex Therapeutics Inc (CLDX) - Narx/daromad koeffitsiyenti|P/S multiplikatori AUPH|BCRX: Narxning sotuvga nisbati|Narxning daromadga nisbati Vera Therapeutics, Inc. VERA|dianthustx.com (DNTH) - Sotuvga nisbatan narx|PHVS - Narxning daromadga nisbati|ABCL: Narxning daromadga nisbati|Tourmaline Corp (TRML) - Narxning daromadga nisbati|PGEN - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati PHAR|NKTR: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Upstream Bio (UPB)|Narx/daromad koeffitsiyenti Zenas Bio|Immunome Corp - Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - P/S multiplikatori|SEPN - P/S multiplikatori|PVLA (Pieris Pharmaceuticals, Inc.) - Kapitalizatsiyaning daromadga nisbati|SVRA - Narx/daromad koeffitsiyenti|RIGL (Rigel Pharmaceuticals Inc) - P/S multiplikatori|ANAB - Narx/daromad multiplikatori|Narxning daromadga nisbati Astria Therapeutics (ATXS)|ENGN (engene.com) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori RAPT (RAPT Therapeutics)|JBIO (Aerovate Therapeutics, Inc.) - Narxning sotuvga nisbati|ACRS - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Narxning daromadga nisbati|Narxning sotuvga nisbati CABA (cabalettabio.com)|VTYX (Ventyx Biosciences, Inc.) - P/S multiplikatori|THTX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori AVTX|P/S multiplikatori Eledon Pharmaceuticals, Inc (ELDN)|Narxning daromadga nisbati Agenus AGEN|Bozor kapitallashuvining daromadga nisbati CLYM|ZURA - Narxning daromadga nisbati|aTyr Pharma Inc (ATYR) - Kapitalizatsiyaning daromadga nisbati|ADAG: P/S multiplikatori|Ikena Oncology (IMA) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati STTK|EQ: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori CNTB|Narx/daromad koeffitsiyenti immunic-therapeutics.com|Narxning daromadga nisbati Atara Bio ATRA|IFRX - Kapitalizatsiyaning daromadga nisbati|XFOR - Narxning daromadga nisbati|Adicet Bio (ACET) - Kapitalizatsiyaning daromadga nisbati|CELU (celularity.com) - Kapitalizatsiyaning daromadga nisbati|INmune Bio Inc (INMB) - P/S multiplikatori|Narxning daromadga nisbati Barinthus Bio|Kapitalizatsiya va daromad nisbati KZR (Kezar Life Sciences Inc)|P/S multiplikatori SABS|AKTX - Sotuvga nisbatan narx|P/S multiplikatori ENLV (Enlivex Therapeutics Ltd.)|Narx/daromad multiplikatori Q32 Bio Inc|GOVX - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati EDSA (Edesa Biotech Corp)|IBIO: P/S multiplikatori|CARM - Narx/daromad koeffitsiyenti|XTLB (XTL Biopharmaceuticals Ltd.) - P/S multiplikatori|Bolt Bio - Narxning sotuvga nisbati|Narxning daromadga nisbati HCW Biologics Inc. (HCWB)|APVO - Sotuvga nisbatan narx|Narxning daromadga nisbati AIM ImmunoTech Inc. AIM|Aditxt Inc. - Narxning daromadga nisbati|GRI - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti XORTX Therapeutics Inc XRTX|HIND (ReShape Lifesciences) - Kapitalizatsiyaning daromadga nisbati|Revelation Biosciences Corp - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Indaptus Therapeutics|scinai.com (SCNI) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati CALI (CalciMedica, Inc.)|Narx/daromad koeffitsiyenti affimed.com|P/S multiplikatori ALLK (Allakos)|P/S multiplikatori HOOKIPA Pharma, Inc. HOOK|IGMS: Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti iteostherapeutics.com ITOS|OCEA: P/S multiplikatori|Narx/daromad multiplikatori TC BioPharm (Holdings) Plc TCBP|Narxning daromadga nisbati Third Harmonic Bio, Inc
